Systematic Financial Management LP Has $3.40 Million Stock Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Systematic Financial Management LP has reduced its stake in Maravai LifeSciences to 1,536,183 shares, representing a 6.9% decrease, with a total value of approximately $3.40 million.
• Several other institutional investors also altered their positions, with notable increases including Performa Ltd US LLC, which boosted its holdings by 245.0% in the first quarter.
• Maravai LifeSciences' stock is currently trading at $2.45, with analysts providing mixed ratings; the average target price among them is set at $5.75.

Systematic Financial Management LP lessened its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 6.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,536,183 shares of the company's stock after selling 113,361 shares during the period. Systematic Financial Management LP owned 0.60% of Maravai LifeSciences worth $3,395,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Alyeska Investment Group L.P. grew its holdings in Maravai LifeSciences by 145.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock worth $29,045,000 after acquiring an additional 3,161,072 shares during the period. Ameriprise Financial Inc. grew its holdings in Maravai LifeSciences by 1.8% during the 4th quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company's stock worth $19,683,000 after acquiring an additional 62,123 shares during the period. Bamco Inc. NY grew its holdings in Maravai LifeSciences by 3.8% during the 4th quarter. Bamco Inc. NY now owns 2,203,651 shares of the company's stock worth $12,010,000 after acquiring an additional 80,000 shares during the period. Deutsche Bank AG grew its holdings in Maravai LifeSciences by 67.6% during the 1st quarter. Deutsche Bank AG now owns 2,072,239 shares of the company's stock worth $4,580,000 after acquiring an additional 835,600 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in Maravai LifeSciences by 9.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,447,714 shares of the company's stock worth $7,890,000 after acquiring an additional 127,672 shares during the period. Institutional investors and hedge funds own 50.25% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Craig Hallum reduced their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Royal Bank Of Canada reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 12th. Finally, Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $5.22.

Maravai LifeSciences Stock Up 0.2%

NASDAQ:MRVI traded up $0.01 on Friday, hitting $2.39. 182,913 shares of the company's stock were exchanged, compared to its average volume of 2,349,128. The company has a market cap of $609.04 million, a P/E ratio of -1.75 and a beta of 0.28. The firm has a 50-day moving average price of $2.47 and a 200-day moving average price of $2.45. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.66 and a 52 week high of $9.60. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.